Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Comparisons of EQ-5D-Y and PedsQL in pediatric patients with mild-to-moderate chronic kidney disease in longitudinal analyses.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101153626 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7525 (Electronic) Linking ISSN: 14777525 NLM ISO Abbreviation: Health Qual Life Outcomes Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BioMed Central, c2003-
    • Subject Terms:
      Quality of Life*/psychology ; Renal Insufficiency, Chronic*; Adolescent ; Humans ; Child ; Surveys and Questionnaires ; Reproducibility of Results ; Comorbidity ; Psychometrics
    • Abstract:
      Objective: To characterize longitudinal changes and correlations between the measures of EQ-5D-Y and generic PedsQL and their associations with clinical changes in children and adolescents with mild-to-moderate chronic kidney disease (CKD).
      Methods: Participants were recruited from January 2017 to September 2021 in a medical center in Taiwan. Both instruments were administered in their initial visits and every 6-month subsequent visits. Spearman's Rho (ρ) was used to assess correlations between the scores of EQ-5D-Y and PedsQL measures in longitudinal changes. Cohen's effect size (ES) was used to evaluate the changes of scores/subscales over time. In addition, factors associated with longitudinal changes in the score/subscales were explored.
      Results: A total of 121 participants were enrolled, and 83 with ≥ 3 HRQOL measures during the 3.5 years follow-up were assessed their changes of HRQOL measures. The correlations (ρ > 0.3) appeared between the changes in the visual analog scale (VAS) of EQ-5D-Y and emotional and social subscales of PedsQL. ES was small (< 0.5) in the VAS and level-sum-score (LSS) of EQ-5D-Y scores for the clinical changes in comorbidities, while some PedsQL subscales were medium to high (0.5-0.8 or > 0.8). Hypertension, mineral bone disorder/anemia, and hyperuricemia associated with the changes in both HRQOL scores were varied by their various domains.
      Conclusion: Both EQ-5D-Y and PedsQL of HRQOL measures were responsive to worsened childhood CKD-related comorbidities during the follow-up; however, convergent validity between them was limited in some domains. The LSS of EQ-5D-Y showed greater changes than the VAS by comorbidity status; further comparison with utility weight is needed to determine the better performance of EQ-5D-Y.
      (© 2023. The Author(s).)
    • References:
      Qual Life Res. 2015 Sep;24(9):2195-208. (PMID: 25715946)
      Pediatr Nephrol. 2019 Oct;34(10):1753-1764. (PMID: 31222663)
      Value Health Reg Issues. 2016 May;9:57-62. (PMID: 27881260)
      Pediatr Nephrol. 2023 Feb;38(2):519-528. (PMID: 35678879)
      Int J Integr Care. 2002;2:e15. (PMID: 16896390)
      Int J Mol Sci. 2018 Nov 22;19(12):. (PMID: 30469463)
      Pediatr Nephrol. 2016 Jul;31(7):1113-20. (PMID: 26850057)
      Qual Life Res. 2019 Nov;28(11):3093-3105. (PMID: 31243620)
      Health Qual Life Outcomes. 2013 May 04;11:75. (PMID: 23642162)
      BMC Public Health. 2020 Jun 22;20(1):982. (PMID: 32571279)
      J Am Soc Nephrol. 2009 Mar;20(3):629-37. (PMID: 19158356)
      J Pediatr (Rio J). 2021 Sep-Oct;97(5):478-489. (PMID: 33340460)
      J Pediatr. 2013 Sep;163(3):736-41.e1. (PMID: 23628375)
      Med Care. 2001 Aug;39(8):800-12. (PMID: 11468499)
      Arch Dis Child. 2019 Feb;104(2):134-140. (PMID: 30018070)
      Pediatrics. 2010 Feb;125(2):e349-57. (PMID: 20083528)
      Pediatr Nephrol. 2014 Dec;29(12):2347-56. (PMID: 24908324)
      Health Qual Life Outcomes. 2022 Feb 17;20(1):28. (PMID: 35177084)
      Health Qual Life Outcomes. 2021 Nov 15;19(1):256. (PMID: 34781978)
      Qual Life Res. 2013 Dec;22(10):2889-97. (PMID: 23595412)
      Pediatr Nephrol. 2020 Sep;35(9):1659-1667. (PMID: 32333284)
      Clin Kidney J. 2016 Aug;9(4):583-91. (PMID: 27478602)
      PeerJ. 2017 Mar 21;5:e3115. (PMID: 28344908)
      BMC Pediatr. 2018 Feb 3;18(1):25. (PMID: 29397047)
      Int J Mol Sci. 2019 Oct 24;20(21):. (PMID: 31653115)
      Eur J Health Econ. 2021 Sep;22(7):1083-1093. (PMID: 33893889)
      Pediatr Nephrol. 2021 May;36(5):1307-1310. (PMID: 33547529)
      Pediatr Nephrol. 2006 Apr;21(4):538-44. (PMID: 16511685)
      Pediatr Nephrol. 2016 Oct;31(10):1579-91. (PMID: 26310616)
      BMC Public Health. 2013 Jul 23;13:675. (PMID: 23875722)
      Pediatr Nephrol. 2016 Dec;31(12):2309-2316. (PMID: 27677977)
      Int J Qual Health Care. 2018 May 01;30(4):298-305. (PMID: 29447362)
      J Patient Rep Outcomes. 2022 Jun 16;6(1):67. (PMID: 35708825)
      BMC Public Health. 2014 Apr 04;14:307. (PMID: 24708535)
      Health Qual Life Outcomes. 2017 Jan 19;15(1):12. (PMID: 28103872)
      Qual Life Res. 2010 Aug;19(6):875-86. (PMID: 20405245)
      J Clin Med. 2019 Jul 24;8(8):. (PMID: 31344888)
    • Contributed Indexing:
      Keywords: Chronic kidney disease; EQ-5D-Y; Health-related quality of life; Longitudinal analysis; Pediatrics; PedsQL
    • Publication Date:
      Date Created: 20231027 Date Completed: 20231030 Latest Revision: 20231030
    • Publication Date:
      20231215
    • Accession Number:
      PMC10605985
    • Accession Number:
      10.1186/s12955-023-02197-9
    • Accession Number:
      37891615